FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly//File Photo

REGENXBIO INC placed its experimental gene therapy for a rare inherited disorder on clinical hold on Monday, sending shares down 24% in premarket trading. The action follows spinal scan abnormalities found in five study participants years after treatment.